CoChat

The p53/MDM2/MDMX-targeted therapies – a clinical synopsis

Open access
Jiang, Liren, Zawacka-Pankau, Joanna · 2020 · Cell Death & Disease

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

The cost of cancer care accelerates because of the growing number of cancer patients and the increasing expenses of drug innovations. The approval of costly second-line therapies like immune checkpoint inhibitors or CAR-T therapies contributes to this trend. Hence, drug repurposing, which uses drugs originally approved for other indications, is emerging as a necessary approach in cancer care, due to its comparatively low innovation and treatment costs and predictable side-effects 1 .

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41419-020-2445-9

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Targeting p53/MDM2/MDMX axis for improved cancer therapy. MDM2 and MDMX are critical negative regulators of p53 and p73 transcription activity and protein stability. Both MDM2 and MDMX bind to p53 N-terminus and inhibit its transcription activity (upper panel). Besides, MDM2 monoubiqutinates p53, which induces p53 nuclear export and the inability to regulate the expression of the target genes. Hetero-dimers of MDMX and MDM2 induce enhanced polyubiquitination of p53 and direct it for proteasomal degradation. Small-molecule MDM2 agonists like RG compounds, MI derivatives or AMG-232 are currently in clinical development. The compounds stabilize p53 and restore the wt-p53 function. Exo-PpIX is the only small molecule inhibiting both p53/MDM2 and p53/MDMX interactions. The only dual inhibitor in clinical trials is a stapled peptide ARLN-6924 (upper panel). Both MDM2 and MDMX also inhibit the transcription activity of p73 tumor suppressor by associating with its N-terminus and inhibiting transcription activity (lower panel). The binding of MDM2 enables the binding of ITCH, E3 ubiquitin ligase of p73 and its proteasomal degradation. In addition to p53, exo-PpIX activates p73 through inhibition of the p73/MDM2 and p73/MDMX. Verteporfin, an analog of PpIX, approved by the FDA to treat age-related macular degeneration in combination with light is a promising candidate for drug repurposing in oncology (http://www.redo-project.org/db/). It was shown to activate p73 in TP53 mutant cancer cells presumably through targeting p73/MDM2 interactions similarly to Nutlin17. It remains to be elucidated whether Verteporfin is a dual inhibitor of p53/MDM2/MDMX or p73/MDM2/MDMX interactions. A question mark represents not-fully depicted mechanism. Dashed line indicates that the mechanism is not-fully pictured in the figure due to space restrictions.
Fig. 1 Targeting p53/MDM2/MDMX axis for improved cancer therapy. MDM2 and MDMX are critical negative regulators of p53 and p73 transcription activity and protein stability. Both MDM2 and MDMX bind to p53 N-terminus and inhibit its transcription activity (upper panel). Besides, MDM2 monoubiqutinates p53, which induces p53 nuclear export and the inability to regulate the expression of the target genes. Hetero-dimers of MDMX and MDM2 induce enhanced polyubiquitination of p53 and direct it for proteasomal degradation. Small-molecule MDM2 agonists like RG compounds, MI derivatives or AMG-232 are currently in clinical development. The compounds stabilize p53 and restore the wt-p53 function. Exo-PpIX is the only small molecule inhibiting both p53/MDM2 and p53/MDMX interactions. The only dual inhibitor in clinical trials is a stapled peptide ARLN-6924 (upper panel). Both MDM2 and MDMX also inhibit the transcription activity of p73 tumor suppressor by associating with its N-terminus and inhibiting transcription activity (lower panel). The binding of MDM2 enables the binding of ITCH, E3 ubiquitin ligase of p73 and its proteasomal degradation. In addition to p53, exo-PpIX activates p73 through inhibition of the p73/MDM2 and p73/MDMX. Verteporfin, an analog of PpIX, approved by the FDA to treat age-related macular degeneration in combination with light is a promising candidate for drug repurposing in oncology (http://www.redo-project.org/db/). It was shown to activate p73 in TP53 mutant cancer cells presumably through targeting p73/MDM2 interactions similarly to Nutlin17. It remains to be elucidated whether Verteporfin is a dual inhibitor of p53/MDM2/MDMX or p73/MDM2/MDMX interactions. A question mark represents not-fully depicted mechanism. Dashed line indicates that the mechanism is not-fully pictured in the figure due to space restrictions.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 64

Metadata

Authors
Jiang, L., & Zawacka-Pankau, J.
Affiliations
Shanghai Jiao Tong University (CN)
Venue
Cell Death & Disease
Published
2020-04-17
Volume
11
Issue
4
Pages
237-237
ISSN
2041-4889 (ISSN-L)
OpenAlex
W3016812120
Cited by
62
References
19
Citations by year
2026: 3 · 2025: 5 · 2024: 11 · 2023: 9 · 2022: 15 · 2021: 12 · 2020: 7
FWCI
4.06
Type
journal article
Language
en
Open access
Licence
Locations
  • Cell Death and Disease (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords
p53, MDM2, MDMX, targeted cancer therapy, drug repurposing, cancer treatment costs, immune checkpoint inhibitors, CAR T-cell therapy
MeSH terms
Humans, Tumor Suppressor Protein p53, Proto-Oncogene Proteins c-mdm2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The p53/MDM2/MDMX-targeted therapies – a clinical synopsis. https://app.cochat.ai/papers/10.1038/s41419-020-2445-9
The paper
Jiang, L., & Zawacka-Pankau, J. (2020). The p53/MDM2/MDMX-targeted therapies – a clinical synopsis. Cell Death & Disease. https://doi.org/10.1038/s41419-020-2445-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.